Literature DB >> 16792679

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

S Schilling1, S Goelz, R Linker, F Luehder, R Gold.   

Abstract

Fumaric acid esters (FAE) have proven their therapeutic efficacy in psoriasis, a Th1 mediated skin disease. More recently, preliminary data have suggested an activity in multiple sclerosis (MS) as well. To investigate further possible mechanisms of action of these compounds in inflammatory diseases, we studied the FAE methyl hydrogen fumarate (MHF) and dimethyl fumarate (DMF) in chronic experimental autoimmune encephalomyelitis (EAE) induced by immunization of C57BL/6 mice with MOG peptide aa 35-55. Preventive treatment with these FAE was delivered twice a day by oral gavage. Both esters had a significant therapeutic effect on the disease course and histology showed a strongly reduced macrophage inflammation in the spinal cord. Multiparameter cytokine analysis from blood detected an increase of IL-10 in the treated animals. We conclude that the underlying biological activity of FAE in EAE is complex and, to elucidate the molecular mechanisms, further investigation is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792679      PMCID: PMC1942010          DOI: 10.1111/j.1365-2249.2006.03094.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  T-lymphocyte entry into the central nervous system.

Authors:  W F Hickey; B L Hsu; H Kimura
Journal:  J Neurosci Res       Date:  1991-02       Impact factor: 4.164

2.  Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.

Authors:  U Mrowietz; E Christophers; P Altmeyer
Journal:  Br J Dermatol       Date:  1998-03       Impact factor: 9.302

Review 3.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

4.  Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation.

Authors:  C A Colton; J E Keri; W T Chen; W L Monsky
Journal:  J Neurosci Res       Date:  1993-06-15       Impact factor: 4.164

Review 5.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.

Authors:  R S Liblau; S M Singer; H O McDevitt
Journal:  Immunol Today       Date:  1995-01

6.  Experimental autoimmune encephalomyelitis repressed by microglial paralysis.

Authors:  Frank L Heppner; Melanie Greter; Denis Marino; Jeppe Falsig; Gennadij Raivich; Nadine Hövelmeyer; Ari Waisman; Thomas Rülicke; Marco Prinz; Josef Priller; Burkhard Becher; Adriano Aguzzi
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

7.  Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?

Authors:  K Asadullah; H Schmid; M Friedrich; F Randow; H D Volk; W Sterry; W D Döcke
Journal:  Arch Dermatol Res       Date:  1997-10       Impact factor: 3.017

8.  Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

Authors:  W Brück; A Bitsch; H Kolenda; Y Brück; M Stiefel; H Lassmann
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

9.  Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.

Authors:  R de Jong; A C Bezemer; T P Zomerdijk; T van de Pouw-Kraan; T H Ottenhoff; P H Nibbering
Journal:  Eur J Immunol       Date:  1996-09       Impact factor: 5.532

Review 10.  The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis.

Authors:  T Owens; S Sriram
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

View more
  100 in total

Review 1.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors:  Ralf A Linker; Aiden Haghikia
Journal:  Ther Adv Chronic Dis       Date:  2016-06-10       Impact factor: 5.091

Review 2.  Novel oral agents for multiple sclerosis.

Authors:  Jodie M Burton; Paul O'Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

Review 3.  The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress.

Authors:  Truyen Nguyen; Paul Nioi; Cecil B Pickett
Journal:  J Biol Chem       Date:  2009-01-30       Impact factor: 5.157

Review 4.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

5.  A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies.

Authors:  Alexander M Tatara; Emma Watson; Nathaniel D Albert; Panayiotis D Kontoyiannis; Dimitrios P Kontoyiannis; Antonios G Mikos
Journal:  J Biomed Mater Res A       Date:  2019-04-07       Impact factor: 4.396

Review 6.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments.

Authors:  Michelangelo Certo; Chin-Hsien Tsai; Valentina Pucino; Ping-Chih Ho; Claudio Mauro
Journal:  Nat Rev Immunol       Date:  2020-08-24       Impact factor: 53.106

Review 7.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

8.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

9.  Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation.

Authors:  Henrik Wilms; Jobst Sievers; Uta Rickert; Martin Rostami-Yazdi; Ulrich Mrowietz; Ralph Lucius
Journal:  J Neuroinflammation       Date:  2010-05-19       Impact factor: 8.322

10.  Models of autoimmune demyelination in the central nervous system: on the way to translational medicine.

Authors:  Ralf A Linker; De-Hyung Lee
Journal:  Exp Transl Stroke Med       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.